The Rise of Targeted Kidney Therapies: Redefining Glomerulonephritis

Recent studies highlight a turning point in glomerulonephritis care. This episode reviews new data on C3G outcomes, CAR T-cell therapy for lupus nephritis, and emerging treatments like felzartamab, iptacopan, and SGLT2 inhibitors — marking a shift toward more personalized, targeted kidney therapies.